Bullfrog-Derived GLP-1 Peptide Outperforms Semaglutide and Produces 38% Weight Loss When Combined With Amylin Analog

bGLP-10 showed superior albumin affinity and receptor potency. At 10 nmol/kg, bGLP-10 significantly outperformed semaglutide in blood sugar reduction and food intake suppression (p<0.001). Chronic combination results: bGLP-10 + cagrilintide = -38.4% weight loss (p<0.001) vs semaglutide + cagrilintide = -23.0% vs bGLP-10 alone = -16.1% vs semaglutide alone = -10.9% vs cagrilintide alone = -5.7%. Superior glucose control and liver lipid management vs semaglutide-cagrilintide (p<0.001).

In vitro receptor binding and activation assays. In vivo: diet-induced obesity (DIO) mice on high-fat diet. Acute studies for blood sugar and food intake. Chronic combination study with bGLP-10 and/or cagrilintide vs semaglutide and/or cagrilintide. Outcomes: body weight, blood glucose, liver lipids.

The combination of GLP-1 and amylin analogues is the next frontier in obesity treatment (Novo Nordisk's CagriSema is in phase 3 trials). This study suggests that natural GLP-1 peptides from non-mammalian species may be even more effective than current drugs, and that the right GLP-1-amylin combination could achieve unprecedented weight loss levels.

Nature's peptide diversity is an underexplored resource for drug development. Bullfrog GLP-1 differs from human GLP-1, and these differences may confer therapeutic advantages. The 38.4% weight loss achieved with the bGLP-10-cagrilintide combination approaches surgical levels, suggesting next-generation peptide combinations could match or exceed bariatric surgery outcomes.

Mouse study only — DIO mice don't fully model human obesity. No pharmacokinetic data in larger animals or humans. No safety/tolerability assessment. The comparison to semaglutide may not reflect optimized dosing. bGLP-10 is a novel compound with no clinical development track record.